Gyroscope Therapeutics Holdings plc announced that it will receive up to £44.5 million in an equity round of funding from new investor, Sanofi Ventures on November 8, 2021. The investor will invest £29.666666 million initially, at a premium to company's prior Series C financing, and the remaining £14.833333 million will be invested contingent on a future qualifying investment round and subject to the satisfaction of certain closing conditions. As a part of the transaction, a Sanofi R&D executive will join the company's Clinical Advisory Board.
Gyroscope Therapeutics Holdings plc
Equities
VISN
US40382N1037
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |